MolDX: Inivata, InVisionFirst, Liquid Biopsy for Patients with Lung Cancer

This Local Coverage Determination (LCD) has been revised and published for notice under contract numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, NMI), and 01312 (NV).

Medicare Coverage Database (MCD) Number: L37897

LCD Title: MolDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer

Effective Date: October 14, 2021

Summary of Changes: Under LCD Title added trademark symbol to Inivata and registered symbol to InVisionFirst. Under CMS National Coverage Policy added regulation CMS Internet-Only Manual, Pub. 100-02, Medicare Benefit Policy Manual, Chapter 15, §80 Requirements for Diagnostic X-Ray, Diagnostic Laboratory, and Other Diagnostic Tests and §80.1.1 Certification Changes and updated descriptions to regulations.

Under Bibliography changes were made to citations to reflect AMA citation guidelines and source #33 was updated to the correct citation. Formatting, punctuation, and typographical errors were corrected throughout the LCD. Acronyms were inserted and defined where appropriate throughout the LCD. Inivata™, InVision®, Oncomine™, FoundationOne®, Tam-Seq™ and InVisionFirst® were inserted throughout the LCD where applicable.

Visit the Molecular Diagnostic Services (MolDX) webpage to access the locally hosted MolDX Medicare Coverage Article from the “Covered Tests” or the “Excluded Tests” webpage.

To view the complete listing of locally hosted coverage articles and/or access the Active, Future, or Retired articles available in the CMS MCD, visit the Medicare Coverage Articles webpage.


            Last Updated Wed, 03 Nov 2021 16:14:43 +0000